4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
MedKoo(授权代理)
主营:主营:抗癌化学试剂和激酶抑制剂
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > peptide > MedKoo/P22077/10mg/406569
商品详细MedKoo/P22077/10mg/406569
MedKoo/P22077/10mg/406569
MedKoo/P22077/10mg/406569
商品编号: 406569
品牌: MedKoo
市场价: ¥3000.00
美元价: 1800.00
产地: 美国(厂家直采)
公司:
产品分类: 多肽合成
公司分类: peptide
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍

P22077
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#:406569

CAS#:1247819-59-5

Description:P22077 is a potent and selective ubiquitin-specific protease 7 (USP7) inhibitor. P22077 potently induces apoptosis in NB cells with an intact USP7-HDM2-p53 axis but not in NB cells with mutant p53 or without human homolog of MDM2 (HDM2) expression. P22077 also significantly augmented the cytotoxic effects of doxorubicin (Dox) and etoposide (VP-16) in NB cells with an intact USP7-HDM2-p53 axis. Moreover, P22077 was found to be able to sensitize chemoresistant LA-N-6 NB cells to chemotherapy. In an in vivo orthotopic NB mouse model, P22077 significantly inhibited the xenograft growth of three NB cell lines. USP7-specific inhibitors like P22077 may serve not only as a stand-alone therapy but also as an effective adjunct to current chemotherapeutic regimens for treating NB with an intact USP7-HDM2-p53 axis.

Price and Availability

SizePriceShipping out timeQuantity
10mgUSD 1502 Weeks
25mgUSD 2502 Weeks
50mgUSD 3502 Weeks
100mgUSD 5502 Weeks
200mgUSD 7502 Weeks
500mgUSD 12502 Weeks
1gUSD 22502 Weeks
2gUSD 36502 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-23.Prices are subject to change without notice.

P22077, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 406569Name: P22077CAS#: 1247819-59-5Chemical Formula: C12H7F2NO3S2Exact Mass: 314.98354Molecular Weight: 315.31Elemental Analysis: C, 45.71; H, 2.24; F, 12.05; N, 4.44; O, 15.22; S, 20.34

Synonym:P22077; P-22077; P 22077.

IUPAC/Chemical Name:1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone

InChi Key:RMAMGGNACJHXHO-UHFFFAOYSA-N

InChi Code:InChI=1S/C12H7F2NO3S2/c1-6(16)11-5-9(15(17)18)12(20-11)19-10-3-2-7(13)4-8(10)14/h2-5H,1H3

SMILES Code:CC(C1=CC([N+]([O-])=O)=C(SC2=CC=C(F)C=C2F)S1)=O

Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Additional Information

References

1: Fan YH, Cheng J, Vasudevan SA, Dou J, Zhang H,Patel RH, Ma IT, Rojas Y, ZhaoY, Yu Y, Zhang H, Shohet JM, Nuchtern JG, Kim ES, Yang J. USP7 inhibitorP22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. CellDeath Dis. 2013 Oct 17;4:e867. doi: 10.1038/cddis.2013.400. PubMed PMID:24136231; PubMed Central PMCID: PMC3920959.

2: Dar A, Shibata E, Dutta A. Deubiquitination of Tip60 by USP7determines the activity of the p53-dependent apoptotic pathway. Mol Cell Biol. 2013 Aug;33(16):3309-20. doi: 10.1128/MCB.00358-13. Epub 2013 Jun 17. PubMedPMID: 23775119; PubMed Central PMCID: PMC3753911.

3: Altun M, Kramer HB, Willems LI, McDermott JL, Leach CA, GoldenbergSJ, Kumar KG, Konietzny R, Fischer R, Kogan E, Mackeen MM, McGouran J,Khoronenkova SV, Parsons JL, Dianov GL, Nicholson B, Kessler BM. Activity-based chemical proteomics accelerates inhibitor development for deubiquitylatingenzymes. Chem Biol. 2011 Nov 23;18(11):1401-12. doi: 10.1016/j.chembiol.2011.08.018.PubMed PMID: 22118674.

 

品牌介绍
MedKoo 美帝药库公司以药物化学合成技术为核心,密切结合全球抗癌新药研发领域中的新技术、新理论、新趋势和新的发展方向,不断推出抗癌化合物新品种。 。 美帝药库MedKoo将在中国建立药物化学合成生产基地和多个现代化药物化合物存储仓库。 美帝药库的药物化合物来源于以下几个渠道:自主合成、委托化学合成、合作伙伴、和从国内外市场上选购。 MedKoo美帝药库的抗癌分子库 MedKoo的目标是打造全球规模最大、品种最多、类别最全和质量最好的小分子抗癌化合物库。MedKoo的抗癌药库将由下列5个分子库组成: (1)上市抗癌药库:该库将含有大约100个全球已批准上市的小分子抗癌化合物; (2)抗癌候选药物库:该分子库含有大约400个世界各国正在临床研究中抗癌小分子候选药物; (3)同系抗癌分子库:该分子库将含有多个化学结构类似或抗癌机制类似的分子包; (4)抗癌分子预制模块库:该库主要含有用于组建抗癌目标分子的分子模块包; (5)同位素标记抗癌分子库。